Presentations & Publications

2023

Podium Presentation – Arepally et al, GEST Annual Meeting, May 2023

Liver and Spleen CT Volumetric Analysis after Selective Imageable Y90 Microspheres (Eye90 microspheres®) Administration

Download the Presentation»»

Podium Presentation – Holden et al, SIR Annual Meeting, March 2023

Initial Clinical Experience with a Novel Glass Imageable Yttrium-90 Radioembolization Microsphere for Treating Malignant Liver Tumors

Download the Presentation»»

Publication – Miller et al, JVIR, January 2023

Comparison of Bolus Versus Dual-Syringe Administration Systems on Glass Yttrium-90 Microsphere Deposition in an In Vitro Microvascular Hepatic Tumor Model

Download the Publication»»

Expert Commentary – Bilbao et al, JVIR January 2023

Understanding of Flow Allows Better Tumor Microsphere Coverage

Download the Publication»»

Podium Presentation – Arepally et al, SIO2023, January 2023

CT Based Dosimetry Using Imageable Glass Y-90 (Eye90 microspheres®) : First in Human Analysis

Download the Presentation»»

Podium Presentation – Arepally et al, Spectrum Conference, January 2023

Clinical Use of Investigational Radiopaque Eye90 Microspheres™ for the Treatment of Unresectable Hepatocellular Carcinoma with 3-month Follow-Up

Download the Presentation»»

2022

Podium Presentation – Holden et al, CIRSE Annual Congress, September 2022

First in Human Clinical Trial Evaluating Safety and Effectiveness of Investigational Radiopaque Eye90 Microspheres® for the Treatment of Unresectable Hepatocellular Carcinoma and Metastatic Colorectal Cancer

Download the Presentation»»

Podium Presentation – Best in Physics Winner – Henry et al, AAPM, July 2022

Precision Dosimetry in Yttrium-90 Radioembolization through CT Imaging of Radiopaque Microspheres in a Rabbit Liver Model

Download the Presentation»»

Podium Presentation – Abraham et al, SIR Annual Meeting, June 2022

Novel Radiopaque Y-90 Glass Microspheres (Eye90 microspheres™) for Canine Hepatocellular Carcinoma: Correlation of Microsphere Radiopacity with TOF PET
Radioactivity and mRECIST

Download the Presentation»»

Podium Presentation – Abraham, SIR Annual Meeting, June 2022

What’s new in microspheres: The next generation for radioembolization

Download the Presentation»»

Podium Presentation – Abraham et al, GEST Annual Meeting, May 2022

Novel Hepatic Tumor Microvascular Model for Evaluating the Deposition Characteristics of Y-90 Microspheres

Download the Presentation»»

Publication – Henry et al, EJNMMI Physics, March 2022

Precision dosimetry in yttrium‑90 radioembolization through CT imaging of radiopaque microspheres in a rabbit liver model

Download the Publication»»

2021

Poster Presentation – Miller et al, CIO, October 2021

Evaluating the Effect of Vascularity on Microembolic Performance of Yttrium-90 Microspheres Using a Novel Hepatic Tumor Model

Download the Poster»»

Podium Presentation – Best in GEST Winner – Miller et al, GEST, July 2021

Novel Hepatic Tumor Microvascular Model for Evaluating the Microembolic Characteristics of Y-90 Microspheres

Download the Presentation»»

Podium Presentation – Best in GEST – Henry et al, GEST, July 2021

CT-based Dosimetry in Yttrium-90 Radioembolization Demonstrated in a Rabbit Liver Model

Download the Presentation»»

Publication – Henry et al, Phys Med Biol, March 2021

Post-administration dosimetry in yttrium-90 radioembolization through micro-CT imaging of radiopaque microspheres in a porcine renal model

Download the Publication»»

Corporate Offices

Halifax Office (Main Office)
155 Chain Lake Drive
Unit 32
Halifax, NS B3S 1B3
Canada

T. 902.442.4009

Orange County Office
555 Corporate Drive
Suite 105
Ladera Ranch, CA, 92694
USA

Contact Us!

ABK Biomedical Inc. provides and continues to provide accurate information on its website. However, ABK Biomedical Inc. assumes no responsibility for the accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical Inc. may change the products mentioned, and their stage in development, at any time without notice. ABK Biomedical Inc. is a clinical-stage company engaged in the research and development of new medical devices. Eye90 microspheres® is considered an investigational product and is NOT FDA-approved for use.